A prospective randomised open label study to determine the best dose escalation sceme of dipyridamol added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary preventive therapy for stroke - DOSE study
- Conditions
- Stroke
- Registration Number
- EUCTR2010-022913-25-NL
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
age over 18
CVA or TIA
Patients starting treatment with acetylsalicylic acid combined with dipyridamole according to Dutch treatment standards
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Patients not able to start treatment with acetylsalicylic acid combined with dipyridamole according to Dutch treatment standards
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To determine the best dose escalation scheme of dipyridamole added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary preventive therapy for stroke ;Secondary Objective: How often do patients stop therapy because of headaches?<br>Do in-hospital patient more often get a Ct-scan or MRI?<br>Is there a difference in headaches between CVA patients and TIA patients?<br>Is it possible to identify a specific group of patients that benefits more from one dose escalation scheme than an other group?;Primary end point(s): Headache frequency
- Secondary Outcome Measures
Name Time Method